Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04353973 · ClinicalTrials.gov registry record · NA
Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Cancer Patients
A NA study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- NA
- Development phase
- 256
- Enrollment target
NCT04353973 is a NA study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 256 participants.
The verdict
NCT04353973, a NA study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 256 participants
- Enrollment target
Study Summary
This study aims to determine if web-based eHealth delivery of pre-test and/or post-test counseling in cancer patients and/or those at risk for cancer can provide equal or improved cognitive and affective outcomes when compared to the standard of care delivery model.
Interventions
- OTHER Standard of Care
- OTHER Pre-Test Intervention
- OTHER Post-Test Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 256 participants |
| Start Date | 2020-08-17 |
| Est. Completion | 2025-02-13 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04353973
The ClinicalTrials.gov registry entry for NCT04353973 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 256 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Standard of Care is the first listed.
NCT04353973 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04353973 about?
NCT04353973 is a clinical study titled "Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Cancer Patients". This study aims to determine if web-based eHealth delivery of pre-test and/or post-test counseling in cancer patients and/or those at risk for cancer can provide equal or improved cognitive and affective outcomes when compared to the standard of care delivery model.
What is the current status of trial NCT04353973?
This trial is currently completed. It is a NA study. The enrollment target is 256 participants. The study started on 2020-08-17. Estimated completion is 2025-02-13.
What interventions are being tested in trial NCT04353973?
The interventions under investigation include: Standard of Care (OTHER), Pre-Test Intervention (OTHER), Post-Test Intervention (OTHER).
Who is sponsoring clinical trial NCT04353973?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.